CAR-T Therapy

In a recent breakthrough for cancer treatment, a team of researchers has developed HSP-CAR30, a novel CAR-T cell therapy that has shown remarkable efficacy in treating relapsed or refractory CD30-positive lymphomas—diseases notoriously resistant to conventional therapies.

Key Features of the Innovation

• Targets the CD30 protein, commonly found in Hodgkin lymphoma and CD30-positive T-cell lymphomas.
• Demonstrated 100% overall response rate in Phase I clinical trials—an extraordinary result for heavily pre-treated patients.
• Achieved 50% complete remission, with disease becoming undetectable through imaging and clinical evaluation.